Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) (Descending) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
63187-0037-08 63187-0037 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 1, 2014 In Use
63187-0037-05 63187-0037 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug. 1, 2014 In Use
63187-0020-36 63187-0020 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sept. 4, 2018 In Use
63187-0020-30 63187-0020 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sept. 4, 2018 In Use
63187-0020-21 63187-0020 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sept. 4, 2018 In Use
63187-0020-15 63187-0020 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sept. 4, 2018 In Use
63187-0020-10 63187-0020 Prednisone Prednisone 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sept. 4, 2018 In Use
63187-0002-30 63187-0002 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 1, 2018 In Use
63187-0002-20 63187-0002 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 1, 2018 In Use
63187-0002-15 63187-0002 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 1, 2018 In Use
63187-0002-10 63187-0002 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 1, 2018 In Use
63126-0333-41 63126-0333 Granisetron Hydrochloride Granisetron Hydrochloride 4.0 mg/4mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous July 10, 2021 In Use
63126-0332-11 63126-0332 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous July 10, 2021 In Use
63126-0331-15 63126-0331 Granisetron Hydrochloride Granisetron Hydrochloride 0.1 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 1, 2020 In Use
63020-0536-30 63020-0536 ponatinib hydrochloride Iclusig 10.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 11, 2021 In Use
63020-0225-21 63020-0225 Fruquintinib Fruzaqla 5.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 8, 2023 In Use
63020-0210-21 63020-0210 Fruquintinib Fruzaqla 1.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 8, 2023 In Use
63020-0080-02 63020-0080 Ixazomib Ninlaro 4.0 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 Oct. 31, 2023 No Longer Used
63020-0080-01 63020-0080 Ixazomib Ninlaro 4.0 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 Oct. 31, 2023 No Longer Used
63020-0079-02 63020-0079 Ixazomib Ninlaro 3.0 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 Oct. 31, 2023 No Longer Used
63020-0079-01 63020-0079 Ixazomib Ninlaro 3.0 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 No Longer Used
63020-0078-02 63020-0078 Ixazomib Ninlaro 2.3 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 Oct. 31, 2023 No Longer Used
63020-0078-01 63020-0078 Ixazomib Ninlaro 2.3 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 No Longer Used
63020-0049-01 63020-0049 Bortezomib Velcade 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 13, 2003 In Use
63020-0040-90 63020-0040 Mobocertinib EXKIVITY 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Sept. 15, 2021 In Use
63020-0040-12 63020-0040 Mobocertinib EXKIVITY 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Sept. 15, 2021 In Use
62935-0756-80 62935-0756 Leuprolide acetate Eligard 7.5 mg/.25mL Hormonal Therapy GnRH Agonist Subcutaneous Nov. 1, 2023 In Use
62935-0753-75 62935-0753 Leuprolide Acetate Eligard Hormonal Therapy GnRH Agonist Subcutaneous May 15, 2002 In Use
62935-0752-75 62935-0752 Leuprolide Acetate Eligard Hormonal Therapy GnRH Agonist Subcutaneous May 15, 2002 April 26, 2019 In Use
62935-0461-50 62935-0461 Leuprolide acetate Eligard 45.0 mg/.375mL Hormonal Therapy GnRH Agonist Subcutaneous March 6, 2023 In Use
62935-0453-45 62935-0453 Leuprolide Acetate Eligard Hormonal Therapy GnRH Agonist Subcutaneous Jan. 7, 2005 In Use
62935-0452-45 62935-0452 Leuprolide Acetate Eligard Hormonal Therapy GnRH Agonist Subcutaneous Jan. 23, 2002 April 26, 2019 No Longer Used
62935-0306-40 62935-0306 Leuprolide acetate Eligard 30.0 mg/.5mL Hormonal Therapy GnRH Agonist Subcutaneous Jan. 11, 2024 In Use
62935-0303-30 62935-0303 Leuprolide Acetate Eligard Hormonal Therapy GnRH Agonist Subcutaneous Feb. 26, 2003 In Use
62935-0302-30 62935-0302 Leuprolide Acetate Eligard Hormonal Therapy GnRH Agonist Subcutaneous Feb. 26, 2003 April 26, 2019 In Use
62935-0227-10 62935-0227 Leuprolide acetate Eligard 22.5 mg/.375mL Hormonal Therapy GnRH Agonist Subcutaneous Nov. 27, 2023 In Use
62935-0223-05 62935-0223 Leuprolide Acetate Eligard Hormonal Therapy GnRH Agonist Subcutaneous Aug. 26, 2002 In Use
62935-0222-05 62935-0222 Leuprolide Acetate Eligard Hormonal Therapy GnRH Agonist Subcutaneous Aug. 26, 2002 April 26, 2019 In Use
62856-0799-05 62856-0799 Palonosetron Aloxi 0.5 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 22, 2008 May 31, 2010 No Longer Used
62856-0798-01 62856-0798 Palonosetron hydrochloride Aloxi 0.075 mg/1.5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous May 28, 2014 June 30, 2018 In Use
62856-0797-01 62856-0797 Palonosetron hydrochloride Aloxi 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous May 28, 2014 Oct. 31, 2022 No Longer Used
62856-0796-04 62856-0796 Netupitant and Palonosetron Akynzeo 300.0 mg/1, 0.5 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 Oral Oct. 13, 2014 Oct. 13, 2014 No Longer Used
62856-0796-01 62856-0796 Netupitant and Palonosetron Akynzeo 300.0 mg/1, 0.5 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 Oral Oct. 13, 2014 May 31, 2018 No Longer Used
62856-0724-30 62856-0724 Lenvatinib Lenvima Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET Oral Feb. 13, 2015 In Use
62856-0724-05 62856-0724 Lenvatinib Lenvima Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET Oral Feb. 13, 2015 In Use
62856-0720-30 62856-0720 Lenvatinib Lenvima 10.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET Oral Feb. 13, 2015 In Use
62856-0720-05 62856-0720 Lenvatinib Lenvima 10.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET Oral Feb. 13, 2015 In Use
62856-0718-30 62856-0718 Lenvatinib Lenvima Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET Oral May 13, 2016 In Use
62856-0718-05 62856-0718 Lenvatinib Lenvima Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET Oral May 17, 2016 In Use
62856-0714-30 62856-0714 Lenvatinib Lenvima Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET Oral Feb. 13, 2015 In Use

Found 10,000 results in 7 milliseconds — Export these results